Search
Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis
CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.
9 hours ago
Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions
Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.
Apr 29, 2024
.png){kind=logo}
